Document:

<PAGE>

                                                                     EXHIBIT 4.7

NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"),
OR THE SECURITIES LAWS OF ANY STATE. SUCH SECURITIES MAY NOT BE SOLD OR
OTHERWISE DISPOSED OF UNLESS PURSUANT TO A REGISTERED OFFERING OR BY TRANSFER
EXEMPT FROM REGISTRATION UNDER THE SECURITIES ACT AND APPLICABLE STATE
SECURITIES LAWS.

                          ENERGY BIOSYSTEMS CORPORATION

                          COMMON STOCK PURCHASE WARRANT

No. W-99-__                                                         _____ Shares

         This certifies that, for value received, __________ or registered
assigns (the "holder"), upon due exercise of this Warrant, is entitled to
purchase from Energy BioSystems Corporation, a Delaware corporation (the
"Company"), at any time on or after June 11, 1999 (the "Initial Exercise Date"),
and before the close of business on June 11, 2002, or if not a trading date on
the New York Stock Exchange, the next following trading date (the "Expiration
Date"), all or any part of ________ fully paid and nonassessable Shares (the
"Warrant Shares") of the Common Stock, par value $0.01 per share, of the Company
("Common Stock"), at a purchase price of $2.40 per share (the "Purchase Price"),
both the Purchase Price and the number of Warrant Shares issuable upon exercise
of this Warrant being subject to possible adjustment as provided below.

         This Warrant is hereinafter called the "Warrant." The holder hereof and
all subsequent holders of this Warrant shall be entitled to all rights and
benefits provided to the holder or holders hereof pursuant to the terms of this
Warrant.

         SECTION 1. EXERCISE OF WARRANT. (a) The holder of this Warrant may, at
any time on or after the Initial Exercise Date and on or before the Expiration
Date, exercise this Warrant in whole at any time or in part (but not less than
1,000 Warrant Shares) from time to time for the purchase of the Warrant Shares
or other securities which such holder is then entitled to purchase hereunder
("Warrant Securities") at the Purchase Price (as hereinafter defined). In order
to exercise this Warrant in whole or in part, the holder hereof shall deliver to
the Company (i) a written notice of such holder's election to exercise this
Warrant, which notice shall specify the number of Warrant Shares to be
purchased, (ii) payment of the aggregate purchase price of the Warrant Shares
being purchased by certified or bank cashier's check, unless pursuant to a
Cashless Exercise as described in subsection (b) below, and (iii) this Warrant,
provided that, if such Warrant Shares or other Warrant Securities have not then
been registered under the Securities Act or applicable state securities laws,
the Company may require that such holder furnish to the Company a written
statement that such holder is purchasing such Warrant Shares or other Warrant
Securities for such holder's own account for investment and not with a view to
the distribution thereof, that none of such shares will be offered or sold in
violation of the provisions of the Securities Act and applicable state
securities laws and as to such other matters relating to the holder as the
Company may reasonably request to permit the issuance of such Warrant Shares or
other Warrant Securities without registration under the Securities Act and
applicable state securities laws. Upon receipt thereof, the Company shall, as
promptly as practicable, execute or cause to be executed and deliver to such
holder a certificate or certificates representing the aggregate number of
Warrant Shares (or if applicable, other Warrant Securities) specified in said
notice. The stock certificate or certificates so delivered shall be in the
denomination of 100 shares each or such other denominations as may be specified
in said notice and shall be registered in the name of such holder or such other
name as shall be designated in said notice.

                                Page 1 of 8
<PAGE>

         No fractional Warrant Shares are to be issued upon the exercise of this
Warrant, but the Company shall pay a cash adjustment in respect of any fraction
of a share which would otherwise be issuable in an amount equal to the same
fraction of the fair market value per share of the Warrant Shares on the day of
exercise, as reasonably determined by the Company. If this Warrant shall have
been exercised only in part, the Company shall, at the time of delivery of said
certificate or certificates, deliver to such holder a new Warrant evidencing the
rights of such holder to purchase the remaining Warrant Shares called for by
this Warrant, which new Warrant shall in all other respects be identical with
this Warrant, or, at the request of such holder, appropriate notation may be
made on this Warrant and same returned to such holder. The Company shall pay all
expenses, taxes and other charges payable in connection with the preparation,
execution and delivery of share certificates under this Section, except that, if
such share certificates are requested to be registered in a name or names other
than the name of the holder of this Warrant, funds sufficient to pay all stock
transfer taxes which shall be payable upon the execution and delivery of such
share certificates shall be paid by the holder hereof at the time of delivering
the notice of exercise mentioned above.

         The Company represents, warrants and agrees that all Warrant Shares
issuable upon any exercise of this Warrant in accordance herewith shall be
validly authorized and issued, fully paid and nonassessable.

         This Warrant shall not entitle the holder hereof to any of the rights
of a stockholder of the Company prior to exercise in the manner herein provided.

         (b) Notwithstanding anything in subsection (a) to the contrary, the
holder of this Warrant may elect to exercise this Warrant in part (but not for
less than 1,000 Warrant Shares) or in whole, at any time on or after the Initial
Exercise Date and on or before the Expiration Date, by the surrender of this
Warrant (with the cashless exercise form at the end hereof duly executed) (a
"Cashless Exercise") at the address set forth in subsection 6(a) hereof. Such
presentation and surrender shall be deemed a waiver of the holder's obligation
to pay the Purchase Price, or the proportionate part thereof if this Warrant is
exercised in part. In the event of a Cashless Exercise, the Holder shall
exchange its Warrant for that number of Warrant Shares or Warrant Securities, as
the case may be, subject to such Cashless Exercise multiplied by a fraction, the
numerator of which shall be the difference between the then Current Market Price
Per Share of the Common Stock and the Per Share Purchase Price, and the
denominator of which shall be the then Current Market Price Per Share of the
Common Stock. For purposes of any computation under this subsection, the then
Current Market Price shall be based on the trading day prior to the Cashless
Exercise. "Current Market Price") shall be deemed to be the last sale price of
the Common Stock on the trading day prior to such date or, in case no such
reported sales take place on such day, the average of the last reported bid and
asked prices of the Common Stock on such day, in either case on the principal
national securities exchange on which the Common Stock is admitted to trading or
listed, or if not listed or admitted to trading on any such exchange, the
representative closing bid price of the Common Stock as reported by the National
Association of Securities Dealers, Inc. Automated Quotations System ("NASDAQ"),
or other similar organization if NASDAQ is no longer reporting such information,
or, if the Common Stock is not reported on NASDAQ, the high per share bid price
for the Common Stock in the over-the-counter market as reported by the National
Quotation Bureau or similar organization, or if not so available, the fair
market value of the Common Stock as determined in good faith by the Board of
Directors.

         SECTION 2. TRANSFER, DIVISION AND COMBINATION. The Company shall keep
at its principal executive office a register for the registration of, and
registration of transfers of, the Warrants. The name and address of each holder
of one or more Warrants, each transfer thereof and the name and address of each
transferee of one or more Warrants shall be registered in such register. Prior
to due presentment for registration of transfer, the person in whose name any
Warrants shall be registered shall be deemed and

                                Page 2 of 8
<PAGE>

treated as the owner and holder thereof for all purposes hereof, and the
Company shall not be affected by any notice or knowledge to the contrary. The
Company shall give to any holder of a Warrant promptly upon request therefor,
a complete and correct copy of the names and addresses of all registered
holders of Warrants.

         Subject to the provisions of Section 3, upon surrender of any Warrant
at the principal executive office of the Company for registration of transfer or
exchange (and in the case of a surrender for registration of transfer, duly
endorsed or accompanied by a written instrument of transfer duly executed by the
registered holder of such Warrant or his attorney duly authorized in writing and
accompanied by the address for notices of each transferee of such Warrant or
part thereof), the Company shall execute and deliver, at the Company's expense,
one or more new Warrants (as requested by the holder thereof) in exchange
therefor, exercisable for an aggregate number of Warrant Shares equal to the
number of shares for which the surrendered Warrant is exercisable and issued to
such person or persons as such holder may request, which Warrant or Warrants
shall in all other respects be identical with this Warrant.

         Upon receipt by the Company of evidence reasonably satisfactory to it
of the ownership of and the loss, theft, destruction or mutilation of any
Warrant, and (a) in the case of loss, theft or destruction, of indemnity
reasonably satisfactory to it (provided that if the holder of such Warrant is,
or is a nominee for, an original holder, such person's own unsecured agreement
of indemnity shall be deemed to be satisfactory), or (b) in the case of
mutilation, upon surrender and cancellation thereof, the Company at its own
expense shall execute and deliver, in lieu thereof, a new Warrant identical in
all respects to such lost, stolen, destroyed or mutilated Warrant.

         SECTION 3. COMPLIANCE WITH SECURITIES ACT; RESTRICTIONS ON TRANSFER AND
SALE. (a) Each certificate for Warrant Shares (or other Warrant Securities)
initially issued upon the exercise of this Warrant and each certificate for
Warrant Shares (or other Warrant Securities) issued to subsequent transferees of
any such certificate shall (unless otherwise permitted by this Section 3) be
stamped or otherwise imprinted with legend in substantially the following form:

         "THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
         REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
         "SECURITIES ACT") OR THE SECURITIES LAWS OF ANY STATE. SUCH SECURITIES
         MAY NOT BE SOLD OR OTHERWISE DISPOSED OF UNLESS PURSUANT TO A
         REGISTERED OFFERING OR BY TRANSFER EXEMPT FROM REGISTRATION UNDER THE
         SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS."

         (b) The holder understands that Warrant Shares (or other Warrant
Securities) which may be acquired by it upon exercise of this Warrant shall be
entitled to certain registration rights provided for in the Subscription
Agreement relating to the purchase and issuance of the Shares and this Warrant
between the Company and the holder. The holder further acknowledges and agrees
that no more than one-third of the Warrant Shares (or other Warrant Securities)
which may be acquired upon exercise hereof may be sold by the holder or any
transferee in any twelve month period.

         SECTION 4. ADJUSTMENT OF PURCHASE PRICE.

         (a) The Purchase Price and the number of Warrant Shares and the number
or amount of any other securities and property as hereinafter provided for which
this Warrant may be exercisable shall be subject to adjustment from time to time
effective upon each occurrence of any of the following events.

         (b) If the Company shall declare or pay any dividend with respect to
its Common Stock payable in shares of Common Stock, subdivide the outstanding
Common Stock into a greater number of

                                Page 3 of 8
<PAGE>

shares of Common Stock, or reduce the number of shares of Common Stock
outstanding (by stock split, reverse stock split, reclassification or
otherwise than by repurchase of its Common Stock) (any of such events being
hereinafter called a "Stock Split"), the Purchase Price and number of Warrant
Shares issuable upon exercise of this Warrant shall be appropriately adjusted
so as to entitle the holder hereof to receive upon exercise of this Warrant,
for the same aggregate consideration provided herein, the same number of
shares of Common Stock (plus cash in lieu of fractional shares) as the holder
would have received as a result of such Stock Split had such holder exercised
this Warrant in full immediately prior to such Stock Split.

         (c) If the Company shall merge or consolidate with or into one or more
corporations or partnerships and the Company is the sole surviving corporation,
or the Company shall adopt a plan of recapitalization or reorganization in which
the Common Stock is exchanged for or changed into another class of stock or
other security or property of the Company, the holder of this Warrant shall, for
the same aggregate consideration provided herein, be entitled upon exercise of
this Warrant to receive in lieu of the number of shares of Common Stock as to
which this Warrant would otherwise be exercisable, the number of shares of
Common Stock or other securities (plus cash in lieu of fractional shares) or
property to which such holder would have been entitled pursuant to the terms of
the agreement or plan of merger, consolidation, recapitalization or
reorganization had such holder exercised this Warrant in full immediately prior
to such merger, consolidation, recapitalization or reorganization.

         (d) If the Company is merged or consolidated with or into one or more
corporations or partnerships under circumstances in which the Company is not the
sole surviving corporation, or if the Company sells or otherwise disposes of
substantially all its assets, and in connection with any such merger,
consolidation or sale the holders of Common Stock receive stock or other
securities convertible into equity of the surviving or acquiring corporations or
entities, or other securities or property after the effective date of such
merger, consolidation or sale, as the case may be, the holder of this Warrant
shall, for the same aggregate consideration provided herein, be entitled upon
exercise of this Warrant to receive, in lieu of the shares of Common Stock as to
which this Warrant would otherwise be exercisable, shares of such stock or other
securities (plus cash in lieu of fractional shares) or property as the holder of
this Warrant would have received pursuant to the terms of the merger,
consolidation or sale had such holder exercised this Warrant in full immediately
prior to such merger, consolidation or sale. In the event of any consolidation,
merger or sale as described in this Section 4(d), provision shall be made in
connection therewith for the surviving or acquiring corporations or partnerships
to assume all obligations and duties of the Company hereunder or to issue
substitute warrants in lieu of this Warrant with all such changes and
adjustments in the number or kind of shares of stock or securities or property
thereafter subject to this Warrant or in the Purchase Price as shall be required
in connection with this Section 4(d).

         (e) If the Company (other than in connection with a sale described in
Section 4(d)) proposes to liquidate and dissolve, the Company shall give notice
thereof as provided in Section 5(b) hereof and shall permit the holder of this
Warrant to exercise any unexercised portion hereof at any time within the 10 day
period following delivery of such notice, if such holder should elect to do so,
and participate as a stockholder of the Company in connection with such
dissolution.

         (f) Whenever any adjustment is made as provided in any provision of
this Section 4:

                           (i) the Company shall compute the adjustments in
                  accordance with this Section 4 and shall prepare a certificate
                  signed by an officer of the Company setting forth the adjusted
                  number of shares or other securities or property and Purchase
                  Price, as applicable, and showing in reasonable detail the
                  facts upon which such adjustment is based, and such
                  certificate shall forthwith be filed with the Company or its
                  designee; and

                                Page 4 of 8
<PAGE>

                           (ii) a notice setting forth the adjusted number of
                  shares or other securities or property and the Purchase Price,
                  as applicable, shall forthwith be required, and as soon as
                  practicable after it is prepared, such notice shall be
                  delivered by the Company to the holder of record of each
                  Warrant.

         (g) If at any time, as a result of any adjustment made pursuant to this
Section 4, the holder of this Warrant shall become entitled, upon exercise
hereof, to receive any shares other than shares of Common Stock or to receive
any other securities, the number of such other shares or securities so
receivable upon exercise of this Warrant shall be subject to adjustment from
time to time in a manner and on terms as nearly equivalent as practicable to the
provisions contained in this Section 4 with respect to the Common Stock.

         SECTION 5.  SPECIAL AGREEMENTS OF THE COMPANY.

         (a) The Company covenants and agrees that it will reserve and set apart
and have at all times a number of shares of authorized but unissued Common Stock
(and, if applicable, other Warrant Securities) then deliverable upon the
exercise of the Warrants or any other rights or privileges provided for therein
sufficient to enable it at any time to fulfill all its obligations thereunder;
and if at any time the number of authorized but unissued shares of Common Stock
shall not be sufficient to effect the exercise of this Warrant at the Purchase
Price then in effect, the Company will take such corporate action as may, in the
reasonable opinion of its counsel, be necessary to increase its authorized
shares but unissued shares of Common Stock (and, if applicable, other Warrant
Securities) to such number of shares as shall be sufficient for such purposes.

         (b)      In case the Company proposes

                  (i) to pay any dividend upon the Common Stock or make any
         distribution or offer any subscription or other rights to the holders
         of Common Stock, or

                  (ii) to effect any capital reorganization or reclassification
         of capital stock of the Company, or

                  (iii) to effect the consolidation, merger, sale of all or
         substantially all of the assets, liquidation, dissolution or winding up
         of the Company,

then the Company shall cause notice of any such intended action to be given to
each holder of the Warrants not less than 15 nor more than 60 days prior to the
date on which the transfer books of the Company shall close or a record be taken
for such dividend or distribution, or the date when such capital reorganization,
reclassification, consolidation, merger, sale, liquidation, dissolution or
winding up shall be effected, or the date of such other event, as the case may
be.

         SECTION 6. NOTICES. Any notice or other document required or permitted
to be given or delivered to holders of Warrants and holders of Common Stock (or
other Warrant Securities) shall be in writing and sent (a) by telecopy if the
sender on the same day sends a confirming copy of such notice by a recognized
overnight delivery service (charges prepaid), or (b) by registered or certified
mail with return receipt requested (postage prepaid) or (c) by a recognized
overnight delivery service (with charges prepaid).

                  (i) if to the Company, at Energy BioSystems Corporation, 4200
         Research Forest Drive, The Woodlands, Texas 77381, Telecopy No.: (281)
         364-6110, or such other address as it shall have specified to the
         holders of Warrants in writing; or

                                Page 5 of 8
<PAGE>

                  (ii) if to a holder, at its address set forth below, or such
         other address as it shall have specified to the Company in writing.

Notices given under this Section 6 shall be deemed given only when actually
received.

         SECTION 7. AMENDMENT. This Warrant may not be amended, modified or
otherwise altered in any respect except by the written consent of the registered
holder of this Warrant and the Company.

         SECTION 8. SUCCESSORS AND ASSIGNS. This Warrant shall be binding upon
and inure to the benefit of the Company and the holder of this Warrant and their
respective successors and permitted assigns.

         SECTION 9. GOVERNING LAW. This Warrant shall be governed by and
construed in accordance with the laws of the State of Delaware, without
reference to the conflicts of law principles thereof.

                  IN WITNESS WHEREOF, the Company has caused this Warrant to be
signed in its name by its duly authorized officers and accepted by the holder of
this Warrant this 11th day of June, 1999.

ATTEST:                                 ENERGY BIOSYSTEMS CORPORATION

By:                                     By:
    --------------------------             -------------------------------
Name:    Paul G. Brown, III                     William E. Nasser
Title:  Secretary                               President

Address for Notices:

------------------------------------

------------------------------------

------------------------------------

                                Page 6 of 8
<PAGE>

SUBSCRIPTION

                  The undersigned, ___________________, pursuant to the
provisions of the foregoing Warrant, hereby agrees to subscribe for and purchase
____________________ shares of the Common Stock, par value $.01 per share, of
Energy BioSystems Corporation covered by said Warrant, and makes payment
therefor in full at the price per share provided by said Warrant.

Dated:__________________                   Signature:____________________

Signature Guarantee:                       Address:______________________

________________________                   Social Security No. _____________

                                CASHLESS EXERCISE

                  The undersigned ___________________, pursuant to the
provisions of the foregoing Warrant, hereby elects to exchange its Warrant for
___________________ shares of Common Stock, par value $.01 per share, of Energy
BioSystems Corporation pursuant to the Cashless Exercise provisions of the
Warrant.

Dated:__________________                   Signature:____________________

Signature Guarantee:                       Address:______________________

________________________                   Social Security No.:_____________

                                   ASSIGNMENT

                  FOR VALUE RECEIVED _______________ hereby sells, assigns and
transfers unto ____________________ (SS#_________________) the foregoing Warrant
and all rights evidenced thereby, and does irrevocably constitute and appoint
_____________________, attorney, to transfer said Warrant on the books of Energy
BioSystems Corporation.

Dated:__________________                   Signature:____________________

Signature Guarantee:                       Address:______________________

------------------------

                                Page 7 of 8
<PAGE>

                               PARTIAL ASSIGNMENT

                  FOR VALUE RECEIVED _______________ hereby assigns and
transfers unto ____________________ (SS#________________) the right to purchase
_______ shares of the Common Stock, par value $.01 per share, of Energy
BioSystems Corporation covered by the foregoing Warrant, and a proportionate
part of said Warrant and the rights evidenced thereby, and does irrevocably
constitute and appoint ____________________, attorney, to transfer that part of
said Warrant on the books of Energy BioSystems Corporation.

Dated:_______________                      Signature:____________________

Signature Guarantee:                       Address:______________________

---------------------

                                Page 8 of 8<PAGE>

                                                                 EXHIBIT 10.3

                      SPONSORED LABORATORY STUDY AGREEMENT

         THIS Agreement is made this 4th day of October, 2000, between The
University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard,
Houston, Texas 77030 ("Institution"), a component of The University of Texas
System ("System"), and Enchira Biotechnology Corporation, 4200 Research
Forest Drive, The Woodlands, Texas 77381 ("Sponsor"), to conduct a laboratory
study and evaluation ("Study"). Institution and Sponsor agree as follows:

                                 1. PROTOCOL

1.1 Institution agrees to use its best efforts to conduct the Study, as an
independent contractor, in accordance with Institutional policy, applicable
laws and regulations and the Project, "Directed Evolution of Growth Factors
and Receptors" as described in Exhibit A attached hereto and incorporated
herein. The Study will be supervised by Mein-Chie Hung, Ph.D., ("Principal
Investigator"), at Institution, with assistance from associates and
colleagues as required.

1.2 Sponsor agrees to engage the services of Institution to conduct the Study.

                                  2. AWARD

2.1 In consideration for performance of the Study by Institution, Sponsor
shall pay Institution Three Hundred Thousand and No/l00 Dollars ($300,000.00)
for Study expenses and other related costs. This amount, shown by approximate
category of expense in Exhibit B attached hereto for information only, is
payable in eight (8) quarterly installments in the amount of Thirty-Seven
Thousand Five Hundred and NO/100 Dollars ($37,500.00) each. The first payment
is payable within thirty (30) days of written notification from M.D. Anderson
that the research has commenced.

2.2 Institution shall provide Sponsor with quarterly written reports
summarizing the research done and all results obtained in the Study.

                                  3. TERM

3.1 This Agreement shall continue in force until the earlier of completion of
the Study as mutually agreed upon in writing by the parties or twenty-four
(24) months from the date set forth above; provided, however, that either
party may terminate the Agreement by giving thirty (30) days advance written
notice to the other.

3.2 Upon early termination of this Agreement, Sponsor shall be liable for all
reasonable costs incurred or obligated by Institution at the time of such
termination, subject to the maximum amount specified in Article 2. Sponsor
shall pay Institution for such costs within thirty (30) days of receipt of an
invoice for same.

3.3 Upon termination of this Agreement, Institution shall return Sponsor's
materials and equipment to Sponsor.

<PAGE>

                             4. INDEMNIFICATION

4.1 Institution shall, to the extent authorized under the Constitution and
laws of the State of Texas, indemnify and hold Sponsor harmless from
liability resulting from the negligent acts or omissions of Institution, its
agents or employees pertaining to the activities to be carried out pursuant
to the obligations of this Agreement; provided, however, that Institution
shall not hold Sponsor harmless from claims arising out of the negligence or
willful malfeasance of Sponsor, its officers, agents, or employees, or any
person or entity not subject to Institution's supervision or control.

4.2 Sponsor shall indemnify and hold harmless System, Institution, their
Regents, officers, agents and employees from any liability or loss resulting
from judgments or claims against them arising out of the activities to be
carried out pursuant to the obligation of this Agreement, including but not
limited to the use by Sponsor of the results of the Study; provided, however,
that the following is excluded from Sponsor's obligation to indemnify and
hold harmless: the negligent failure of Institution to comply with any
applicable governmental requirements or to adhere to the terms of the
Protocol; or the negligence or willful malfeasance by a Regent, officer,
agent, or employee of Institution or System.

                     5. PUBLICATION AND CONFIDENTIALITY

5.1 Subject to section 5.3, the Sponsor shall have the option to issue press
releases concerning the establishment of the Agreement and scientific
publications, presentations and expanded collaborations resulting from the
Study.

5.2 The parties reserve the right to publish or otherwise make public the
data resulting from the Study. The party so wishing to publish or make public
shall submit any such manuscript or release to the other party for comment
thirty (30) days prior to submission for publication or release.

5.3 Except as otherwise required by law or regulation, neither party shall
release or distribute any press release, materials or information containing
the name of the other party or any of its employees without prior written
approval by an authorized representative of the non-releasing party, but such
approval shall not be unreasonably withheld

5.4 Each party shall hold in confidence during the term of this Agreement and
for three (3) years after the termination of this Agreement any confidential
information identified as confidential and obtained from the other party
during the course of this Study. Nothing herein, however, shall prevent
Institution or any other component of System from using any information
generated hereunder by Institution for ordinary non-commercial research and
educational purposes of a university.

                           6. INTELLECTUAL PROPERTY

6.1. Title to all inventions and discoveries conceived by Institution
resulting from the research performed hereunder shall reside in Institution;
title to all inventions and discoveries conceived by Sponsor resulting from
the research performed hereunder shall reside in Sponsor; title to all
inventions and discoveries conceived jointly by Institution and Sponsor
resulting from the research performed hereunder shall reside jointly in
Institution and Sponsor.

<PAGE>

Inventorship shall be determined in accordance with U.S. Patent law. Such
inventions solely or jointly conceived by Institution shall be "Institution
Inventions".

6.2 After consultation with Sponsor regarding the advisability of filing
patent applications, Institution shall file appropriate United States and
foreign patent applications for Institution Inventions. Institution will
provide Sponsor, on a confidential basis, a copy of any such application to
be filed and any documents received or to be filed during prosecution thereof
and will provide Sponsor the opportunity to comment thereon. On any
application on which an employee of Sponsor is named as a co-inventor,
Sponsor will cooperate in obtaining execution of any necessary documents by
its employees.

6.3 Institution grants Sponsor a first option to negotiate an exclusive,
worldwide, royalty-bearing license under Institution Inventions conceived
during the term of this Agreement or within six (6) months thereafter and
Patent rights claiming such Institution Inventions. Institution shall
promptly notify Sponsor in writing of all Institution Inventions and Sponsor
shall have three (3) months from written disclosure of each Institutional
Invention to notify Institution of its desire to enter into such a license
agreement, and a license agreement shall be negotiated in good faith and on
commercially reasonable terms within a period not to exceed six (6) months
from Sponsor's written notification to Institution of its desire to enter
into a license agreement, or such period of time as to which the parties
shall mutually agree.

6.4 Sponsor and Institution fail to enter into an agreement during that
period of time, Sponsor shall have a right of first refusal with respect to
any terms generally more favorable offered by Institution to a third party.

6.5 If In the event Sponsor elects to exercise its option and enters an
exclusive license in accordance with the procedures detailed above, it shall
be obligated to pay all expenses, including attorney's fees, incurred in
searching prior art, obtaining search opinions, preparing applications,
filing, prosecuting, enforcing or maintaining a patent or patent application
with respect to the licensed invention in any country in which the patent or
application is filed.

                                7. GENERAL

7.1 This Agreement, including the attached Exhibit A and B, constitutes the
entire and only Agreement between the parties relating to the Study, and all
prior negotiations, representations, agreements, and understandings are
superseded hereby. No agreements altering or supplementing the terms hereof,
including the exhibits attached hereto, may be made except by a written
document signed by the duly authorized representatives of the parties.

7.2 Any conflicts between the Project and this Agreement are controlled by
this Agreement.

7.3 This Agreement shall be construed and enforced in accordance with the
laws of the State of Texas.

7.4 This Agreement anticipates educational training and may involve health
science postgraduates and other students of the Institution.

<PAGE>

IN WITNESS WHEREOF, Institution and Sponsor hereby enter into this Agreement,
effective as of the date first set forth above, and execute two (2) original
counterparts.

Enchira Biotechnology Corporation      The University of Texas M.D.
                                       Anderson Cancer Center

By:                                    By:
Peter P. Policastro, Ph.D.             Leonard A. Zwelling, M.D., M.B.A
President and CEO                      Vice President for Research
Administration

Date: 10/4/00                          Date:  10/5/00

I acknowledge that I have read this Agreement in its entirety and that I
shall use reasonable efforts to uphold my individual obligations and
responsibilities set forth herein:

By:                                    Mien-Chie Hung, Ph.D.
                                       Principal Investigator

Make Payment to:
The University of Texas
M.D. Anderson Cancer Center
Attn: Manager, Grants & Contracts Accounting
P.O. Box 297402
Houston, TX 77297
Tax I.D. 746001118 A1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00023-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00023-of-00352.parquet"}]]